TLDR:
- Carlsmed, a personalized surgery medtech company, raised $52.5M in Series C funding.
- The funding round was led by B Capital and U.S. Venture Partners.
Carlsmed, a Carlsbad, CA-based AI-enabled personalized surgery medtech company, has secured $52.5M in Series C funding. The round was led by B Capital and U.S. Venture Partners. The company, led by CEO Mike Cordonnier, has developed the aprevo ® personalized surgery platform, aimed at advancing the standard of care for spine surgery. The funds will be used to speed up the commercialization of the aprevo ® personalized spine surgery platform for lumbar fusion procedures and the development of aprevo ® for cervical fusions slated for launch in 2025. Mike Cordonnier highlighted that their AI-enabled technology platform and innovative business model allow them to scale production rapidly to meet growing demand and empower patients.
